All News

healthcare.costs_.jpg

Drug Pricing Regulations in US and Canada

d Jack Cush, MD

Reuters reports on regulatory efforts by Canada and the US to curb the rising cost of drugs, especially expensive new medicines. 

Read Article
acupuncture.jpg

Pilot Study Targets Insulin Resistence in Fibromyalgia

d Jack Cush, MD

An unusual pilot study has shown that insulin resistence (IR), assessed by Hgb-A1c levels, was more prevalent in fibromyalgia (FM) patients compared to non-diabetic controls and that when FM patients were given metformin, half had complete resolution of their pain.

Read Article
cells.vessel.traffic.wbc_.jpg

Monocyte Patrolling Contributes to Lupus Glomerulonephritis

d Jack Cush, MD

Systemic lupus erythematosus (SLE) is an autoimmune disease with a propensity to develop glomerulonephritis (47-70%) or end-stage kidney disease despite therapy.

Read Article
XRAYworse.jpg

Denosumab Protects Against RA Erosions

d RheumNow

Combining denosumab (Prolia) with a conventional disease-modifying antirheumatic drug (DMARD) such as methotrexate showed promise for slowing radiographic damage in rheumatoid arthritis (RA), a manufacturer-sponsored phase III trial called DESIRABLE found.

Read Article
CDC.Front_.jpg

CDC: One in Four US Adults have Arthritis

d Jack Cush, MD

MMWR reports that in 2017, one in four US adults have arthritis (range from 22.8% to 34.6%), with higher rates in Appalachia and Lower Mississippi Valley regions. Of those with arthritis, 31% reported to have "severe arthritis".

Read Article
FDA has approved Ruzurgi (amifampridine) for Lambert-Eaton myasthenic syndrome in children 6-17 years. Drug works by blocking potassium channel efflux in nerve terminals, opening Ca2+ channels & increasing acetylcholine release https://t.co/y7JFr76PTr

Links:

Dr. John Cush RheumNow ( View Tweet)

Long term safety of Secukinumab in PsO, PsA, & AS RCTs ( 96,054 patient-years) - favorable results with low incidence of serious infx (1.4, 1.9, 1.2, /100PYs), Candida (2.2, 1.5, 0.7/100pYs), IBD (0.01, 0.05, and 0.1/100PYs) or MACE (0.3, 0.4, 0.6). No TB. https://t.co/BTbBlOYj8W

Links:

Dr. John Cush RheumNow ( View Tweet)

In mice infected with the ZIKA virus, use of IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury by inhibiting microglial activation in the perinatal brain and by direct effects on the placenta. https://t.co/pgcOBoXMux

Links:

Dr. John Cush RheumNow ( View Tweet)

Danish population study of 55,037 found 210 men (37.6% RF+) & 456 women (41% RF+) RA pts; In women, body fat%, waist size, & obesity was assoc. w/ higher risk of RA. (10% higher for each 5% body fat, 5% for each 5- cm in waist, & 50% higher for obese) https://t.co/PRUBWcWXjC

Links:

Dr. John Cush RheumNow ( View Tweet)

Claims comparison of venous thromboembolic events (VTE) in treated RA pts finds a nonsignificant, but numerically higher rate of VTE in TOFA vs TNFi pts (0.60/100PY vs 0.34/100PY) (1.12/100PY vs 0.92/100PY), respectively. HR 1.33 (95% CI 0.78–2.24). https://t.co/JygSou07B1

Links:

Dr. John Cush RheumNow ( View Tweet)

A bit of welcome data on this -> Abatacept concentrations in maternal serum and breast milk during breastfeeding and an infant safety assessment https://t.co/TypfZZgcdK

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)

New data on tocilizumab in pregnancy, upshot is: "Tocilizumab concentrations in cord blood and infant serum were 80–90% of those in maternal serum" https://t.co/qV7758L4Pm

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)

In first-degree relatives of RA patients, comparing ACPA pos and neg FDR finds all moderate to severe periodontitis was significantly more prevalent in ACPA+ FDR (91%) compared to ACPA neg FDR (40%). From the Journal of Clinical Periodontology https://t.co/5d4YKGszZO

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up – DESIREABLE Results (5.3.19) WATCH it here https://t.co/uyYKxw21Kd or listen to the PODCAST on iTunes (Apple Car Play) or SoundCloud here>> https://t.co/HW0aDJo90Q

Links:

Dr. John Cush RheumNow ( View Tweet)

Cohort study finds 6/420 (1.4%) of SLE patients had steroid induced pancreatitis is - half of them died. Lit review finds 451 lupus pancreatitis with majority developing pancreatitis w/in 3 days of medium-to-high dose steroids (mortality = 37.5%). https://t.co/QsIHsl44qx

Links:

Dr. John Cush RheumNow ( View Tweet)

“..the only difference between those who have failed and those who have succeeded lies in the difference of their habits —I will form good habits and become their slave. - from The greatest Salesman in the World

Dr. John Cush RheumNow ( View Tweet)

Eight Survival skills (cont) 5) Set a daily goal and track your progress. 6) find a daily "hassle" & reframe it in a more positive light. 7) Do something nice for someone else each day. 8) Practice mindfulness by paying attention to the present moment https://t.co/8uX7Db7QdB

Links:

Dr. John Cush RheumNow ( View Tweet)

Eight Survival skills (from NPR article) to manage stress: 1) identify one positive event each day.2) Tell someone or share that positive event. 3) Start a daily gratitude journal. 4) Whats your personal strength and how have you used it; https://t.co/8uX7Db7QdB

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 281 Italian pts with temporal artery Bx-proven Giant cell arteritis shows increased mortality w/ large vessel involvement (HR 5.14) at diagnosis, and reduced mortality with PMR onset (HR 0.57) & adventitial inflammation (HR 0.31) on TABx. https://t.co/iF90cqYtqn

Links:

Dr. John Cush RheumNow ( View Tweet)

Recent Methotrexate use lowers Cardivascular risk by 20% finds a Study of 23,994 elderly RA patients. 13.7% had a CVE (28.5 events per 1000 PY; 95% CI 27.6–29.5). https://t.co/yyR5DUTfF8

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×